Wednesday, March 11, 2009
Tuesday, February 14, 2006
According to a meta-analysis reported by Dr. Lee Simon, Associate Clinical Professor of Medicine at Harvard Medical School, the COX-2 specific inhibitor Celebrex (celecoxib) is not associated with an increased risk of serious cardiovascular thrombotic events compared to placebo or NSAIDs. This meta-analysis, which covered 41 clinical studies involving 44,308 patients, evaluated the cardiovascular safety of Celebrex versus both placebo and nonselective NSAIDs ("ns-NSAIDs").
In summary, the meta-analysis showed that patients taking Celebrex had no more risk for heart attack, stroke, or CV death combined than those given placebo or ns-NSAIDs.
Dr. Simon presented his report about the meta-analysis at the American College of Rheumatology (ACR) 2005 Annual Scientific Meeting, held in mid-November at San Diego, California. Some of his findings included:
“There were no cardiovascular signals that were any different to the active comparators. [Celebrex] was no different to non selective drugs in terms of cardiovascular risk,” Dr. Simon said. Comparators included placebo, naproxen, diclofenac, ibuprofen, loxoprofen, acetaminophen and ketoprofen.
“In this large meta-analysis comprising studies of two weeks to three years duration involving patients with chronic conditions, [Celebrex] at doses of 200mg or more total daily dose was not associated with an increased risk of serious CV thromboembolic events compared with placebo or nonselective NSAIDs,” Dr Simon concluded.
Dr. Simon is a former Division Director of the Arthritis, Analgesic & Ophthalmologic Drug Product Division at the FDA's Center for Drug Evaluation and Research.
This meta-analysis was reportedly funded by the drug company Pfizer, which makes Celebrex. Dr. Gail Cawkwell, a Senior Medical Director at Pfizer, said that this meta-analysis presented by Dr. Simon at the 2005 ACR meeting was being prepared for publication in a peer-reviewed journal. Further, Dr. Cawkwell said the new meta-analysis data had been shared with the FDA as well as European Union regulators.
In summary, the meta-analysis showed that patients taking Celebrex had no more risk for heart attack, stroke, or CV death combined than those given placebo or ns-NSAIDs.
Dr. Simon presented his report about the meta-analysis at the American College of Rheumatology (ACR) 2005 Annual Scientific Meeting, held in mid-November at San Diego, California. Some of his findings included:
“There were no cardiovascular signals that were any different to the active comparators. [Celebrex] was no different to non selective drugs in terms of cardiovascular risk,” Dr. Simon said. Comparators included placebo, naproxen, diclofenac, ibuprofen, loxoprofen, acetaminophen and ketoprofen.
“In this large meta-analysis comprising studies of two weeks to three years duration involving patients with chronic conditions, [Celebrex] at doses of 200mg or more total daily dose was not associated with an increased risk of serious CV thromboembolic events compared with placebo or nonselective NSAIDs,” Dr Simon concluded.
Dr. Simon is a former Division Director of the Arthritis, Analgesic & Ophthalmologic Drug Product Division at the FDA's Center for Drug Evaluation and Research.
This meta-analysis was reportedly funded by the drug company Pfizer, which makes Celebrex. Dr. Gail Cawkwell, a Senior Medical Director at Pfizer, said that this meta-analysis presented by Dr. Simon at the 2005 ACR meeting was being prepared for publication in a peer-reviewed journal. Further, Dr. Cawkwell said the new meta-analysis data had been shared with the FDA as well as European Union regulators.
Monday, January 30, 2006
Does anyone you know suffer from this problem they are ashamed to talk about,
even to their close friends or to their doctor?
Help is now at hand.
even to their close friends or to their doctor?
Help is now at hand.
Many people with bladder control problems hide the problem from everyone, even from their doctor. There is no need to do that. In most cases urinary incontinence can be treated and controlled, if not cured. If you are having bladder control problems, you don’t need to suffer in silenceor to feel ashamed about it. You are not alone.
Talk to your doctor. About 80 percent of people with urinary incontinence can be cured or improved.
Urinary incontinence means that you can’t always control when you urinate. As a result, you wet your clothes.
The National Association For Continence (NAFC) of the US estimates that about 25 million adults in the United States experience urinary incontinence, the involuntary leakage of urine. Women experience it twice as often as men. Incontinence is embarrassing, and debilitating to many. It wakes them up at night, restricts their time away from home, irritates their skin, forces them to wear bulky pads or diapers, and makes them self-conscious.
Although incontinence can occur at any age, age-related changes in the body make older people more likely to experience it. But no matter what your age, if you feel that bladder symptoms are affecting the quality of your life, it’s time to do something about it.
Talk to your doctor. About 80 percent of people with urinary incontinence can be cured or improved.
Urinary incontinence means that you can’t always control when you urinate. As a result, you wet your clothes.
The National Association For Continence (NAFC) of the US estimates that about 25 million adults in the United States experience urinary incontinence, the involuntary leakage of urine. Women experience it twice as often as men. Incontinence is embarrassing, and debilitating to many. It wakes them up at night, restricts their time away from home, irritates their skin, forces them to wear bulky pads or diapers, and makes them self-conscious.
Although incontinence can occur at any age, age-related changes in the body make older people more likely to experience it. But no matter what your age, if you feel that bladder symptoms are affecting the quality of your life, it’s time to do something about it.
Subscribe to:
Posts (Atom)
